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Background
Recombinant products have reached the market in
diverse areas, including pharmaceutical, veterinary food,
pesticides and detergents. Noteworthy, approximately
30 recombinant products in the pharmaceutical sector
account for more than 90 per cent of all recombinant
product sales. Although microbial systems can be con-
sidered an attractive option for expressing certain bio-
pharmaceutical proteins, many biopharmaceutical
molecules are too large and complex and need to be
expressed in mammalian cells.
The most reported cell lines used for industrial pro-
cesses are CHO, NS0, Sp2/O-Ag14 and HEK293. In par-
ticular, the latter has been gaining significant
importance in the biopharmaceutical field during the
last two decades. While initially employed for adenoviral
vector production HEK293 became also one of the pre-
ferred cell lines for transient or stable protein expres-
sion. This is mainly due to its high transfection
efficiency. Meanwhile genetic manipulation also includes
new techniques for directing the integration of the for-
eign gene to highly expressed chromosomal sites e.g. by
RMCE.
In this work, three strategies for recombinant protein pro-
duction in HEK293 cells have been compared (Figure 1):
(St.1) rAdV production expressing protein of interest, (St.2)
stable cell line establishment by random gene transfection
or (St.3) site-specific integration using RMCE technology.
As protein of interest we used the Cap protein from the
capsid of porcine circovirus serotype 2 (CAP-PCV2). This
virus is related to post weaning multisystemic wasting syn-
drome (PMWS), which has major implications for the pig
industry worldwide.
Materials and methods
Strategy 1. CapPCV2 recombinant Adenovirus
Viral DNA was isolated from field and the gene of the
capsid (CapPCV2) was cloned into Adh5 genome using
AdEasyXL kit. Virus and protein production were per-
formed by infecting HEK293-F6 suspension cells [1].
Strategy 2. HEK293 stable cell line by random integration
CapPCV2 gene sequence was codon optimized for
mammalian cell expression. The obtained sequence was
cloned into pIRESpuro3 bicistronicvector [2]. HEK293-
F6 suspension cells were transfected (PEI-DNA method)
and positive cell pool was selected by puromycin addi-
tion to the media.
Strategy 3. HEK293 stable cell line by RMCE
Three targeting vectors encoding for different promoters
were transfected by electroporation to three different
HEK293 master cell lines. Positive clones were selected by
neomycin and ganciclovir addition to media. Clones were
isolated by single colony pick up. Upon the selection of
the best promoter, RMCE was applied to 293T cell line
[3]. Positive clones were selected by puromycin addition to
media and single colony isolation was carried out. The
selected clone was finally adapted to grow in suspension.
Results
We generated transient Cap-PCV2 producer cells by
infection of the HEK293 cell line with a recombinant
adenovirus (rAdV-Cap) (Figure 1, left panel). This
approach gave a specific production (qp) of (41.291 ±
0.0002)e-3pg/cell, which is considerably low (Table 1).
In contrast, a significant increase in production was
achieved upon random integration of a CapPCV2
encoding plasmid (Figure 1B) which resulted in a 2.5-
fold increment of qp (0.107 ± 0.018pg/cell). The best
results were obtained upon the site directed integration
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using RMCE technology (Figure 1C). Using this
approach, CapPCV2 gene was inserted into previously
identified chromosomal hotspots. The specific produc-
tion of the RMCE-derived stable cell line (0.226 ± 0.034
pg/cell) doubled the one of the cell line obtained by ille-
gitimate integration. Nevertheless, the highest volu-
metric productivity was calculated for the stable cell line
after illegitimate integration (103.14 ± 8.6 ng/(mL·day)).
This is related to the capacity of this cell line to grow in
suspension in contrast to the adherent cell growth of
the RMCE-derived cell line. The high cell densities
achieved in cell suspension culture (≈18e6 cell/mL) [4]
can compensate the lower qpof the cell line.
Conclusions
The main conclusion of this work is that a bioprocess
based on site-integrated stable suspension cell line
would be the preferred one not only because the highest
qp, but also due to the easy characterization of the pro-
cess (in comparison to adenovirus infection), the repeat-
ability of batch productions (in comparison to the other
approaches) and the possibility of rapid substitution of
the protein of interest.
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Figure 1 Schematic representation of the three approaches studied for CapPCV2 protein production.







Adenoviral infection (41.291 ± 0.0002)e-3 20.85 ± 0.84 9.25 ± 0.60
Illegitimate integration 0.107 ± 0.018 327.34 ± 62.53 103.14 ± 8.6
Site-directed integration 0.226 ± 0.034 256.57 ± 21.28 64.11 ± 0.13
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